Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNYSEAMERICAN:BVXOTCMKTS:IPHYFNASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$6.01+7.5%$5.09$3.55▼$11.16$462.85M1.132.84 million shs2.95 million shsBVXBovie Medical$6.48+1.1%$6.48$2.28▼$7.70$215.14MN/A136,878 shs129,500 shsIPHYFInnate Pharma$1.45$2.13$1.45▼$1.76$121.55M0.551,445 shsN/AORICORIC Pharmaceuticals$5.41+6.5%$5.84$3.90▼$14.67$384.59M1.37641,722 shs385,131 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+7.51%+10.68%+36.28%-4.45%-16.76%BVXBovie Medical0.00%0.00%0.00%0.00%0.00%IPHYFInnate Pharma0.00%0.00%0.00%-50.00%-34.09%ORICORIC Pharmaceuticals+6.50%-5.09%+9.96%-45.08%-39.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.1755 of 5 stars3.51.00.00.01.63.30.6BVXBovie MedicalN/AN/AN/AN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AN/AN/AN/AORICORIC Pharmaceuticals4.4735 of 5 stars4.52.00.04.32.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20236.11% UpsideBVXBovie Medical 0.00N/AN/AN/AIPHYFInnate Pharma 0.00N/AN/AN/AORICORIC Pharmaceuticals 3.00Buy$19.17254.28% UpsideCurrent Analyst Ratings BreakdownLatest BVX, ORIC, IPHYF, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025ORICORIC PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICORIC PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/20/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/28/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform2/26/2025ORICORIC PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $22.002/26/2025ORICORIC PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K23,142.71N/AN/A$2.75 per share2.19BVXBovie MedicalN/AN/AN/AN/AN/AN/AIPHYFInnate Pharma$66.71M1.82N/AN/A$0.70 per share2.07ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%N/ABVXBovie MedicalN/AN/A0.00∞N/AN/AN/AN/AN/AIPHYFInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/AORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%N/ALatest BVX, ORIC, IPHYF, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 million2/18/2025Q4 2024ORICORIC Pharmaceuticals-$0.52-$0.51+$0.01-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ABVXBovie MedicalN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87BVXBovie MedicalN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AORICORIC PharmaceuticalsN/A10.5613.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%BVXBovie MedicalN/AIPHYFInnate PharmaN/AORICORIC Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%BVXBovie MedicalN/AIPHYFInnate Pharma31.89%ORICORIC Pharmaceuticals6.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5077.01 million68.21 millionOptionableBVXBovie MedicalN/A33.20 millionN/ANot OptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableORICORIC Pharmaceuticals8071.09 million67.09 millionOptionableBVX, ORIC, IPHYF, and ALT HeadlinesRecent News About These CompaniesDimensional Fund Advisors LP Acquires 103,237 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 13 at 3:22 AM | marketbeat.comBalyasny Asset Management L.P. Purchases 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 11 at 5:30 AM | marketbeat.comQ2 EPS Forecast for ORIC Pharmaceuticals Raised by AnalystMay 10 at 7:46 AM | marketbeat.comWedbush Raises Earnings Estimates for ORIC PharmaceuticalsMay 10 at 2:35 AM | americanbankingnews.comOppenheimer Cuts ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $12.00May 8, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)May 8, 2025 | marketbeat.comORIC Pharmaceuticals Outlines Clinical Development Plans and Financial Updates for ORIC-944 and ORIC-114May 7, 2025 | nasdaq.comORIC Pharmaceuticals (NASDAQ:ORIC) Releases Earnings Results, Beats Estimates By $0.10 EPSMay 7, 2025 | marketbeat.comORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC WainwrightMay 7, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)May 7, 2025 | americanbankingnews.comWhy ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Down 7.54%May 6, 2025 | aaii.comORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational UpdatesMay 5, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 5, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 180,140 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 5, 2025 | marketbeat.comBoxer Capital Management LLC Purchases Shares of 1,732,571 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 4, 2025 | marketbeat.comORIC Pharmaceuticals (ORIC) Projected to Post Earnings on MondayMay 4, 2025 | americanbankingnews.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comAdage Capital Partners GP L.L.C. Has $4.04 Million Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 2, 2025 | marketbeat.comWhy ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 7.27%April 30, 2025 | aaii.comORIC Pharmaceuticals (ORIC) to Release Earnings on MondayApril 30, 2025 | marketbeat.comORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual MeetingApril 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBroadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskBy Leo Miller | April 17, 2025View Broadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskIs Alphabet Misunderstood? Here’s Why the Bulls Are BuyingBy Ryan Hasson | April 21, 2025View Is Alphabet Misunderstood? Here’s Why the Bulls Are BuyingWhy Smart Investors Don’t Panic in Election SeasonBy Sarah Horvath | April 24, 2025View Why Smart Investors Don’t Panic in Election SeasonBVX, ORIC, IPHYF, and ALT Company DescriptionsAltimmune NASDAQ:ALT$6.01 +0.42 (+7.51%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$6.04 +0.03 (+0.42%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Bovie Medical NYSEAMERICAN:BVX$6.48 +0.07 (+1.09%) As of 12/31/2018Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.Innate Pharma OTCMKTS:IPHYF$1.45 0.00 (0.00%) As of 05/9/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.ORIC Pharmaceuticals NASDAQ:ORIC$5.41 +0.33 (+6.50%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$5.35 -0.06 (-1.11%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
